Startup Turns to Liquified Silk for Tissue Regeneration

A Boston-area plastic surgery startup wants to use a reverse-engineered form of an ancient medical material in tissue regeneration for aesthetics and medical purposes. Sofregen is working on tissue regeneration using liquefied silk protein, which has emerged from academic research in recent decades. Liquefied silk protein offers biocompatibility and engineering controllability without using harsh chemicals, according to Sofregen chief medical officer Anh Hoang. Hear Anh Hoang discuss the use of silk protein in implantable devices on April 18, 2018, at BIOMEDevice Boston. Use promo code "MDDI" for 20% off conference registration and free expo access. “It’s already used in sutures and mesh,” Hoang said. “We can control how much protein content there is. We can control the mechanics of it.” Silk has been used in medical applications for about 2,000 years, but the first mass-produced, sterile silk sutures were invented by Johnson &Johnson in 1887. Working with technology developed at Tufts University and the University of Pittsburgh, Sofregen is developing a silk scaffold that can be injected to provide immediate bulking of tissue and eventually help it regenerate. It has applied for FDA approval. The first indication would be to bulk up vocal folds so they can come together to produce the sounds used for speech. After the initial bulking, the silk scaffold would be replaced by the patient’s own tissue over the course of 2...
Source: MDDI - Category: Medical Devices Authors: Tags: BIOMEDevice Boston Materials Source Type: news

Related Links:

Allergy,Volume 0, Issue ja, -Not available-.
Source: Allergy - Category: Allergy & Immunology Authors: Source Type: research
Allergy,Volume 0, Issue ja, -Not available-.
Source: Allergy - Category: Allergy & Immunology Authors: Source Type: research
Pediatric Allergy and Immunology,Volume 0, Issue ja, -Not available-.
Source: Pediatric Allergy and Immunology - Category: Allergy & Immunology Authors: Source Type: research
Saratoga Springs, NY - Stewart ’s Shops Corp. is recalling units of Stewart’s Shops brand Cranberry Apple Refresher 16 fluid oz. because the product may contain undeclared milk. People who have an allergy to milk run the risk of serious or life-threatening allergic reaction if they consume this product. Approximately 2,300 u nits of affected product were distributed in upstate New York and Southern Vermont.
Source: Food and Drug Administration - Category: Food Science Source Type: news
Steps outlined for health systems to establish comprehensive, ongoing procurement strategies
Source: The Doctors Lounge - Psychiatry - Category: Psychiatry Tags: Cardiology, Dermatology, Endocrinology, Family Medicine, Geriatrics, Gastroenterology, Gynecology, Infections, AIDS, Internal Medicine, Allergy, Critical Care, Emergency Medicine, Nephrology, Neurology, Nursing, Oncology, Ophthalmology, Orthopedics, ENT, Source Type: news
Publication date: Available online 5 October 2018Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Manuel Jorge Rial, Marcela Valverde-Monge, Aida Gómez-Cardeñosa, Rosialzhira Vera-Berríos, Carlos Pastor-Vargas, Javier Cuesta-Herranz
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Updated Date: Oct 18, 2018 EST
Source: DailyMed Drug Label Updates - Category: Drugs & Pharmacology Source Type: alerts
(La Jolla Institute for Allergy and Immunology) Researchers at La Jolla Institute for Immunology (LJI) and UC San Diego have been awarded $ 4.5 million as part of the National Cancer Institute's Cancer Moonshot initiative. The funding will support research to develop new and improved immunotherapeutic treatment options for patients with head and neck cancer.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
(Technical University of Munich (TUM)) Allergen-specific immunotherapy can considerably improve everyday life for allergy sufferers. It is unclear, however, what exactly happens during this treatment. A team at the Technical University of Munich (TUM) and Helmholtz Zentrum M ü nchen investigated the processes taking place in the body over the course of a three-year allergen-specific immunotherapy. The researchers found clues as to why the allergy immunization takes so long and how the chances of success can be determined at a very early stage.
Source: EurekAlert! - Biology - Category: Biology Source Type: news
Primary Immunodeficiency Disorders
Source: Immunology and Allergy Clinics of North America - Category: Allergy & Immunology Source Type: research
More News: Academia | Allergy | Allergy & Immunology | Chemistry | Clinical Trials | Conferences | Funding | Medical Devices | Plastic Surgery | Universities